登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C66H68CaF2N4O10 · 3H2O
化学文摘社编号:
分子量:
1209.39
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
atorvastatin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[Ca+2].Fc5ccc(cc5)c6[n](c(c(c6c8ccccc8)C(=O)Nc7ccccc7)C(C)C)CC[C@@H](O)C[C@@H](O)CC(=O)O.Fc1ccc(cc1)c2[n](c(c(c2c4ccccc4)\C(=N\c3ccccc3)\[O-])C(C)C)CC[C@@H](O)C[C@@H](O)CC(=O)[O-].O.O.O
InChI
1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1
InChI key
SHZPNDRIDUBNMH-NIJVSVLQSA-L
General description
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。想获得更多信息和支持，请访问颁布药典的网站。
阿托伐他汀钙是HMG-CoA还原酶的选择性合成抑制剂。它不溶于pH低于4的水性溶液，易溶于甲醇。
阿托伐他汀钙是HMG-CoA还原酶的选择性合成抑制剂。它不溶于pH低于4的水性溶液，易溶于甲醇。
Application
阿托伐他汀钙USP标准物质可用于指定的质量检测和分析。
也可根据以下美国药典专题用于制备测定和杂质分析用的系统适用性、标准物质、系统适用性储备、鉴定和标准物质储备溶液：
也可根据以下美国药典专题用于制备测定和杂质分析用的系统适用性、标准物质、系统适用性储备、鉴定和标准物质储备溶液：
- 阿托伐他汀钙
- 阿托伐他汀钙片
- 氨氯地平阿托伐他汀片
Analysis Note
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
Other Notes
可能适用相应的销售限制。
Still not finding the right product?
Explore all of our products under 阿托伐他汀钙
flash_point_f
Not applicable
flash_point_c
Not applicable
target_organs
Liver
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 2 - STOT RE 2
存储类别
11 - Combustible Solids
Development and validation of analytical methods for simultaneous estimation of atorvastatin calcium and ezetimibe in combined dosage form.
Rajamanickam, V., et al.
World Applied Sciences Journal, 9.12, 1424-1429 (2010)
Peter Norsk et al.
The Journal of physiology, 593(3), 573-584 (2015-03-17)
Weightlessness in space induces initially an increase in stroke volume and cardiac output, accompanied by unchanged or slightly reduced blood pressure.It is unclear whether these changes persist throughout months of flight.Here, we show that cardiac output and stroke volume increase
Xiao-ling Li et al.
International immunopharmacology, 23(2), 546-549 (2014-12-03)
This study aimed to investigate the efficacy of combined atorvastatin calcium and methylprednisolone for the treatment of multiple sclerosis relapse. Patients with multiple sclerosis (MS) at the relapse phase were randomized to receive either combined treatment of atorvastatin calcium and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1044516-100MG | 04061838671813 |